Rene Gerolami

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

In vitro study of ethanol production, ethanol tolerance, and antimicrobial susceptibility of gut microbes associated with liver diseases.

In vitro study of ethanol production, ethanol tolerance, and antimicrobial susceptibility of gut microbes associated with liver diseases.

Journal: Gut microbes reports

Published: May 04, 2026

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in Prognosis.

Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in Prognosis.

Journal: Biomedicines

Published: March 01, 2026

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: December 03, 2025

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Journal: Journal of hepatology

Published: October 15, 2025

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.

Journal: Liver cancer

Published: August 26, 2025

Nonsurgical hepatocellular carcinoma treated with selective internal radiation therapy and personalized dosimetry: real-life data from French centers.

Nonsurgical hepatocellular carcinoma treated with selective internal radiation therapy and personalized dosimetry: real-life data from French centers.

Journal: Chinese clinical oncology

Published: June 30, 2025

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

Journal: JHEP reports : innovation in hepatology

Published: June 19, 2025

Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma.

Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma.

Journal: Liver cancer

Published: April 03, 2025

Fatal Hepatitis B Reactivation in Absence of Antibody to Hepatitis B Core Antigen in a Lymphoma Patient.

Fatal Hepatitis B Reactivation in Absence of Antibody to Hepatitis B Core Antigen in a Lymphoma Patient.

Journal: Journal of medical virology

Published: December 27, 2024

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

Journal: Lancet (London, England)

Published: October 24, 2024

Thomasclavelia ramosa and alcohol-related hepatocellular carcinoma: a microbial culturomics study.

Thomasclavelia ramosa and alcohol-related hepatocellular carcinoma: a microbial culturomics study.

Journal: Gut pathogens

Published: September 08, 2024

Showing 1-12 of 66

Last Updated: 09/26/2026